Uploaded October 2026 | Updated November 2026, 3 hours ago
Travis Heath talks with Myriam Barthes, co-founder of Journey Clinical, a network supporting therapists who provide ketamine-assisted psychotherapy. Myriam's path ran from finance, management consulting, and AI to psychedelic medicine after her own recovery from trauma following a serious car accident. Together they look at what psychedelics can and cannot do, why preparation, dosing, and integration belong together, and what therapists should consider before bringing these treatments into their work.
**In this episode**
- [01:39] Myriam's path from finance, consulting, and AI, and the car accident that led her to ketamine-assisted therapy
- [03:54] Building Journey Clinical: a collaborative care model, training, and peer consultation for therapists
- [04:55] What is on the horizon: psilocybin and a pipeline of psychedelic clinical trials
- [06:32] Why the experience is "ineffable," and the preparation, dosing, and integration framework
- [08:27] Psychedelics as neutral amplifiers that "show us who we already were"
- [10:14] The inward journey: set and setting, safety, and the therapist's role
- [13:22] "I'm stuck": the doorway for bringing this up with a client, and relief for stuck therapists
- [14:29] Psychedelic-assisted psychotherapy versus taking psychedelics alone at home
- [15:53] What "ego death" means, and working with expectations, hype, and fear
- [23:07] Skepticism among therapists, and whether every therapist needs to practice this
- [25:19] Who may be a good candidate, and why medical screening matters
- [29:15] What integration looks like, from an artist's gallery show to a veteran walking his daughter down the aisle
- [33:56] Difficult experiences and "bad trips" as therapeutic openings
- [38:33] From counterculture to commercialization
- [43:08] Psychedelics and AI: optimization versus a shift in perspective
- [45:45] How therapists can learn more and get trained
Travis Heath talks with Myriam Barthes, co-founder of Journey Clinical, a network supporting therapists who provide ketamine-assisted psychotherapy. Myriam's path ran from finance, management consulting, and AI to psychedelic medicine after her own recovery from trauma following a serious car accident. Together they look at what psychedelics can and cannot do, why preparation, dosing, and integration belong together, and what therapists should consider before bringing these treatments into their work.
**In this episode**
- [01:39] Myriam's path from finance, consulting, and AI, and the car accident that led her to ketamine-assisted therapy
- [03:54] Building Journey Clinical: a collaborative care model, training, and peer consultation for therapists
- [04:55] What is on the horizon: psilocybin and a pipeline of psychedelic clinical trials
- [06:32] Why the experience is "ineffable," and the preparation, dosing, and integration framework
- [08:27] Psychedelics as neutral amplifiers that "show us who we already were"
- [10:14] The inward journey: set and setting, safety, and the therapist's role
- [13:22] "I'm stuck": the doorway for bringing this up with a client, and relief for stuck therapists
- [14:29] Psychedelic-assisted psychotherapy versus taking psychedelics alone at home
- [15:53] What "ego death" means, and working with expectations, hype, and fear
- [23:07] Skepticism among therapists, and whether every therapist needs to practice this
- [25:19] Who may be a good candidate, and why medical screening matters
- [29:15] What integration looks like, from an artist's gallery show to a veteran walking his daughter down the aisle
- [33:56] Difficult experiences and "bad trips" as therapeutic openings
- [38:33] From counterculture to commercialization
- [43:08] Psychedelics and AI: optimization versus a shift in perspective
- [45:45] How therapists can learn more and get trained










